Edition:
United States

Amgen Inc (AMGN.O)

AMGN.O on Nasdaq

204.02USD
16 Aug 2019
Change (% chg)

$4.71 (+2.36%)
Prev Close
$199.31
Open
$201.83
Day's High
$205.46
Day's Low
$200.36
Volume
3,004,345
Avg. Vol
3,099,023
52-wk High
$211.90
52-wk Low
$166.30

About

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN... (more)

Overall

Beta: 1.40
Market Cap(Mil.): $135,588.20
Shares Outstanding(Mil.): 729.67
Dividend: 1.15
Yield (%): 2.48

Financials

  AMGN.O Industry Sector
P/E (TTM): 16.90 29.89 32.67
EPS (TTM): 11.00 -- --
ROI: 11.98 14.89 14.48
ROE: 26.43 16.01 15.78

Amgen wins U.S. patent battle on arthritis drug Enbrel, thwarting Novartis

A U.S. judge on Friday upheld two patents relating to Amgen Inc's blockbuster rheumatoid arthritis drug Enbrel, denying a challenge by Novartis AG, which is seeking to launch a copycat version.

Aug 09 2019

UPDATE 3-Amgen wins U.S. patent battle on arthritis drug Enbrel, thwarting Novartis

Aug 9 A U.S. judge on Friday upheld two patents relating to Amgen Inc's blockbuster rheumatoid arthritis drug Enbrel, denying a challenge by Novartis AG , which is seeking to launch a copycat version.

Aug 09 2019

U.S. court upholds Amgen patents on arthritis drug Enbrel

Aug 9 A U.S. judge on Friday said patents relating to the Amgen Inc's blockbuster rheumatoid arthritis drug Enbrel were valid, denying a challenge by Novartis AG, which is seeking to launch a copycat version.

Aug 09 2019

Roche loses another bid to halt Amgen sales of biosimilar cancer drug

A federal appeals court on Wednesday denied a request by Roche Holdings subsidiary Genentech Inc for a temporary order keeping a biosimilar version of its cancer drug Herceptin marketed by Amgen Inc off the U.S. market.

Aug 07 2019

Amgen results beat estimates, lung cancer trial planned

Amgen Inc on Tuesday said its second-quarter revenue fell 3% due to more competition for its older off-patent drugs, but rising sales of newer medicines helped its results exceed Wall Street forecasts.

Jul 30 2019

UPDATE 3-Amgen results beat estimates, lung cancer trial planned

July 30 Amgen Inc on Tuesday said its second-quarter revenue fell 3% due to more competition for its older off-patent drugs, but rising sales of newer medicines helped its results exceed Wall Street forecasts.

Jul 30 2019

Amgen quarterly revenue dips 3% but profit tops Street expectations

July 30 Amgen Inc on Tuesday said its second-quarter revenue fell 3% due to more competition for its older off-patent drugs, but rising sales of newer medicines helped the company's results exceed Wall Street estimates.

Jul 30 2019

Newer drugs help Eli Lilly top Wall Street quarterly profit estimate

Eli Lilly and Co reported a second-quarter profit that topped Wall Street estimates and raised its 2019 earnings forecast on Tuesday, as higher demand for newer drugs offset increased discounts for the U.S. Medicare program and sales declines of medicines that lost patent protection.

Jul 30 2019

UPDATE 3-Newer drugs help Eli Lilly top Wall Street quarterly profit estimate

July 30 Eli Lilly and Co reported a second-quarter profit that topped Wall Street estimates and raised its 2019 earnings forecast on Tuesday, as higher demand for newer drugs offset increased discounts for the U.S. Medicare program and sales declines of medicines that lost patent protection.

Jul 30 2019

Amgen bid to stop Neulasta biosimilar fails at Fed Circuit

Amgen Inc on Monday lost a bid to revive a lawsuit it filed seeking to block Coherus BioSciences Inc from selling a biosimilar version of its blockbuster chemotherapy drug Neulasta.

Jul 29 2019
Reuters.com is improving our Quote page. Click here to take a look and let us know what you think.

Earnings vs. Estimates